

**THERMOGENESIS AUTOLOGOUS THROMBIN PROCESSING DEVICE  
(TPD) RECEIVES CE MARK TO ALLOW SALES IN EUROPE**

*Beta Launch to Perfusionists to begin in June*

**Rancho Cordova, California (May 26, 2005) -- THERMOGENESIS CORP. (Nasdaq: KOOL)** announced today that it has been granted the right to affix the CE Mark to the TPD by our European Notified Body. The Company will begin its beta launch of the TPD in June with selected hospital-based perfusionists (blood transfusion specialists) in Belgium, Holland, UK, and Italy as a first step in addressing an annual world market of \$180 million. Full European launch will occur by the end of the summer.

The autologous TPD, a small hand-held disposable that produces 8.5 cc of activated thrombin from 11 cc of patient's own blood plasma in about 25 minutes. Thrombin is a blood clotting enzyme which surgeons use for "topical hemostasis," the treatment of pseudoaneurysms and to form "platelet gels" for the treatment of damaged tissue. These preparations are used in a variety of medical and surgical procedures to control or reduce bleeding.

Kevin Simpson, President and COO of THERMOGENESIS noted "This novel disposable device addresses a strong demand that allows European surgeons to treat patients with thrombin manufactured from their own blood instead of bovine thrombin. Bovine thrombin, rarely used in Europe, has been reported in 28 peer-reviewed journal articles to cause the immune reactions and severe bleeding episodes. Although these health risks and additional concerns about "mad cow disease" have nearly ended the clinical use of bovine thrombin in Europe and Japan, the United States and the rest of the world utilize more than \$180 million annually."

**Regulatory Status**

ThermoGenesis has been granted the right to affix the CE Mark to the CryoSeal FS System by our European Notified Body. The TPD is not available for sale in the U.S., however, a PMA will be prepared to gain FDA clearance for the TPD as a stand-alone product.

**About THERMOGENESIS CORP.**

After extensive research, THERMOGENESIS CORP.'s newly introduced technology platforms lead the world in their ability to produce biological products from single units of blood. Umbilical cord blood banks are utilizing the Company's BioArchive® System as a critical enabling technology for cryogenic archiving of stem cells for transplant, while its CryoSeal FS System is used to prepare hemostatic and adhesive surgical sealants from the patient's blood in about an hour. THERMOGENESIS CORP. has been a leading supplier of state-of-the-art Ultra-Rapid Blood Plasma Freezers and Thawers to hospitals and blood banks since 1992.

*The statements contained in this release which are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company's control with respect to market acceptance of new technologies and products, delays in testing and evaluation of products, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.*

###

[Back to Main Press Page](#)

For More Information, Contact:  
**THERMOGENESIS CORP.**  
Kevin Simpson: (916) 858-5100